3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Uterine Cervical Neoplasms
4
Uterine Cervical Dysplasia
3
Stomach Neoplasms
2
Neoplasms
2
Atypical Squamous Cells of the Cervix
2
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Squamous Intraepithelial Lesions
1
Precancerous Conditions
1
Papilloma
1
Neoplasms, Squamous Cell
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Interventions
Carboplatin
3
Pemetrexed
2
Paclitaxel
2
Gemcitabine
2
rucaparib
1
relacorilant
1
niraparib
1
nintedanib
1
liposomal doxorubicin
1
atezolizumab
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Pregnancy Tests
1
Ocoxin
1
Nivolumab
1
Human Papillomavirus DNA Tests
1
Fulvestrant
1
E-3810
1
Drug Therapy
1
Darbepoetin alfa
1
Colposcopy
1
Cell Count
1
Biopsy
1
Bevacizumab
1
Acetic Acid
1
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Genital Neoplasms, Female
×
Human Papillomavirus DNA Tests
×
Clear all
NCT06815939
2026-01-29
OPTICS
DL Analytics
Phase NA
Recruiting
10,000 enrolled